RxDoctor Payments Data

Sandra Hubbard

Adult Health · Picayune, MSNPI 1063682060

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Pfizer at 39.3% of the total.

$1,236in general payments, 2019–2025

Across 65 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$485
  • Novartis$172
  • Baxter Healthcare$107
  • Abbott$99
  • Merck$83
  • Esperion Therapeutics, Inc.$77
  • plus $212 from 7 others

What the payments were for

  • Food & beverage$1,236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,236 in reported general payments places this provider in the 65th percentile of 93 adult health providers in Mississippi.

See all adult health providers in Mississippi

Medicare billing

Part B allowed, 2024
$30,015
Medicare patients
206
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban691$729,749
XareltoRivaroxaban157$189,612
EntrestoSacubitril/Valsartan77$87,727
Repatha SureclickEvolocumab57$57,377
JardianceEmpagliflozin25$37,825
Metoprolol Succinate1,134$15,698
BrilintaTicagrelor13$9,935
Potassium Chloride196$4,318
Propafenone Hcl82$4,159
Irbesartan233$3,686
Atorvastatin Calcium452$3,133
ClopidogrelClopidogrel Bisulfate389$3,033
Telmisartan111$2,803
Losartan Potassium310$2,364
Olmesartan Medoxomil211$2,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$485$729,749691 claims
Johnson & JohnsonXarelto$40$189,612157 claims
NovartisEntresto$172$87,72777 claims
AstraZenecaBrilinta$15$9,93513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 93 adult health providers in Mississippi.

Other adult health in Picayune

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →